Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Lab Invest. 2008 Nov 10;89(1):80–90. doi: 10.1038/labinvest.2008.103

Figure 2. EBV LMP2 DNA sequencing revealed a mutation interfering with primer binding.

Figure 2

DNA sequencing was performed on a 130bp region of EBV LMP2 encompassing the 69bp region targeted by the LMP2 Q-PCR assay. The forward and reverse primer binding sites for the LMP2 Q-PCR assay are in bold font, while the TaqMan probe site is underlined. The star represents the position of a point mutation (C>T base substitution at position 733) in LMP2 exon 4 of Central American Case #49, which is predicted to result in substitution of serine by phenylalanine; this substitution of a large nonpolar for a small polar amino acid may have functional significance in addition to its apparent interference with laboratory testing.